SM
KZIA

Sabby Management’s Kazia Therapeutics KZIA Stock Holding History

Sabby Management’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-7,333
Closed – – 172
2017
Q4 		$0 Buy
+7,333
New +$1.08M ﹤0.01% 179

Other funds holding KZIA

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RE
RBC Europe London, United Kingdom $2.08B AUM 12.2% 1-Year Est. Return

Sabby Management's KZIA Position: Q1 2018 in Review

Sabby Management sold out of Kazia Therapeutics (KZIA) in Q1 2018, closing a stake of 7,333 shares.

Sabby Management first reported a position in KZIA in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 6 funds tracked by Wall St. Rank hold KZIA as of Q1 2018.

  • Sabby Management reported no remaining Kazia Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Sabby Management sold 7,333 Kazia Therapeutics shares in Q1 2018.
  • Sabby Management first reported a position in Kazia Therapeutics in Q4 2017 and held it in 1 quarter.
  • Sabby Management's Kazia Therapeutics position peaked at $0 in Q4 2017.
  • 6 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q1 2018.

Based on Sabby Management's 13F filing for Q1 2018, filed 15 May 2018.